These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36800249)

  • 1. Successful neoadjuvant treatment of EGFR exon 19 deletion combined with TP53 mutation in non-small cell lung cancer using aumolertinib after osimertinib-induced myocardial damage: a case report and literature review.
    Zhang G; Tang X; Zhang X; Qiu X; Lai Q; Li J
    Anticancer Drugs; 2023 Sep; 34(8):954-961. PubMed ID: 36800249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer.
    van Veggel B; Madeira R Santos JFV; Hashemi SMS; Paats MS; Monkhorst K; Heideman DAM; Groves M; Radonic T; Smit EF; Schuuring E; van der Wekken AJ; de Langen AJ
    Lung Cancer; 2020 Mar; 141():9-13. PubMed ID: 31926441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): A multicenter, single-arm, open-label phase 2b trial.
    Lv C; Fang W; Wu N; Jiao W; Xu S; Ma H; Wang J; Wang R; Ji C; Li S; Wang Y; Yan S; Lu F; Pei Y; Liu Y; Yang Y
    Lung Cancer; 2023 Apr; 178():151-156. PubMed ID: 36863124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aumolertinib Effectively Reduces Clinical Symptoms of an EGFR L858R-Mutant Non-Small Cell Lung Cancer Case Coupled With Osimertinib-Induced Cardiotoxicity: Case Report and Review.
    Zhang Q; Liu H; Yang J
    Front Endocrinol (Lausanne); 2022; 13():833929. PubMed ID: 35677717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With
    Lu S; Dong X; Jian H; Chen J; Chen G; Sun Y; Ji Y; Wang Z; Shi J; Lu J; Chen S; Lv D; Zhang G; Liu C; Li J; Yu X; Lin Z; Yu Z; Wang Z; Cui J; Xu X; Fang J; Feng J; Xu Z; Ma R; Hu J; Yang N; Zhou X; Wu X; Hu C; Zhang Z; Lu Y; Hu Y; Jiang L; Wang Q; Guo R; Zhou J; Li B; Hu C; Tong W; Zhang H; Ma L; Chen Y; Jie Z; Yao Y; Zhang L; Jie W; Li W; Xiong J; Ye X; Duan J; Yang H; Sun M; Sun C; Wei H; Li C; Ali SM; Miller VA; Wu Q
    J Clin Oncol; 2022 Sep; 40(27):3162-3171. PubMed ID: 35580297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful osimertinib rechallenge following subsequent chemotherapy regimen in a patient with metastatic non-small cell lung carcinoma: a case report.
    Han ZJ; Luo N; Li L; Liu ZL
    Ann Palliat Med; 2021 Jul; 10(7):8413-8419. PubMed ID: 33977727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aumolertinib effectively reduces clinical symptoms of an EGFR L858R-mutant non-small cell lung cancer case coupled with osimertinib-induced severe thrombocytopenia: a case report.
    Hu Y; Quan YP; Duan YW; Li H; Shen J; Lin N; Wang C; Tian B; Li JJ
    Anticancer Drugs; 2023 Mar; 34(3):455-459. PubMed ID: 36730569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequence-dependent synergistic effect of aumolertinib-pemetrexed combined therapy on EGFR-mutant non-small-cell lung carcinoma with pre-clinical and clinical evidence.
    Ao L; Fang S; Zhang K; Gao Y; Cui J; Jia W; Shan Y; Zhang J; Wang G; Liu J; Zhou F
    J Exp Clin Cancer Res; 2022 May; 41(1):163. PubMed ID: 35501907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful Treatment with Afatinib after Osimertinib-induced Interstitial Lung Disease in a Patient with EGFR-mutant Non-small-cell Lung Cancer.
    Nishima S; Miyanaga A; Saito S; Yuasa M; Takahashi S; Kashiwada T; Sugano T; Noro R; Minegishi Y; Terasaki Y; Saito Y; Kubota K; Seike M; Gemma A
    Intern Med; 2021 Feb; 60(4):591-594. PubMed ID: 32999231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
    Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M
    Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upfront Use of First-/Second-Generation EGFR-TKI Followed by Osimertinib Shows Better Prognosis than Upfront Osimertinib Therapy in Japanese Patients with Non-small-cell Lung Cancer with Exon 19 Deletion: A Single-Center Retrospective Study.
    Hori T; Yamamoto K; Ito T; Ikushima S; Omura T; Yano I
    Biol Pharm Bull; 2023; 46(6):788-795. PubMed ID: 37258143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel osimertinib-resistant human lung adenocarcinoma cell line harbouring mutant EGFR and activated IGF1R.
    Makimoto G; Ninomiya K; Kubo T; Sunami R; Kato Y; Ichihara E; Ohashi K; Rai K; Hotta K; Tabata M; Maeda Y; Kiura K
    Jpn J Clin Oncol; 2021 May; 51(6):956-965. PubMed ID: 33829270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aumolertinib-based comprehensive treatment for an uncommon site of EGFR exon 20 insertion mutations with multiple metastases non-small cell lung cancer: a case report.
    Deng Y; Yang C; Liu W; Cai S; Guo X
    Anticancer Drugs; 2022 Apr; 33(4):406-412. PubMed ID: 35266890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aumolertinib: A Review in Non-Small Cell Lung Cancer.
    Shirley M; Keam SJ
    Drugs; 2022 Apr; 82(5):577-584. PubMed ID: 35305259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carcinomatosis under control by osimertinib in
    Provenzano L; Cuccarini V; Platania M; Canziani L; Spagnoletti A; Doniselli FM; Eoli M; Prelaj A; Anghileri E
    Tumori; 2021 Dec; 107(6):NP136-NP140. PubMed ID: 34727807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transformation or tumor heterogeneity: Mutations in EGFR, SOX2, TP53, and RB1 persist in the histological rapid conversion from lung adenocarcinoma to small-cell lung cancer.
    Hao L; Chen H; Wang L; Zhou H; Zhang Z; Han J; Hou J; Zhu Y; Zhang H; Wang Q
    Thorac Cancer; 2023 Apr; 14(11):1036-1041. PubMed ID: 36810856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation.
    Li C; Nie W; Guo J; Xiong A; Zhong H; Chu T; Zhong R; Xu J; Lu J; Zheng X; Zhang B; Shen Y; Pan F; Han B; Zhang X
    Respir Res; 2021 May; 22(1):145. PubMed ID: 33975616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Durable clinical benefit from afatinib in a lung adenocarcinoma patient with acquired EGFR L718V mutation-mediated resistance towards osimertinib: a case report and literature review.
    Song Z; Ren G; Wang X; Du H; Sun Y; Hu L
    Ann Palliat Med; 2022 Mar; 11(3):1126-1134. PubMed ID: 35365043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete response to first-line osimertinib monotherapy in a complex epidermal growth factor receptor mutant ( L833V / H835L ) lung adenocarcinoma patient: a case report.
    Luo Z; Luo C; Zhou R; Xiao Y; Wang T
    Anticancer Drugs; 2023 Sep; 34(8):939-941. PubMed ID: 37227041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy analysis of Osimertinib treatment for a patient with leptomeningeal metastasis of EGFR+ non-small cell lung cancer without the T790M mutation.
    Hu X; Chen W; Li X; Zhao C; Zhang C; Xiong F; Wu H
    Ann Palliat Med; 2019 Nov; 8(5):525-531. PubMed ID: 31865717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.